CRISM Therapeutics Corporation
AMMCF
$6.77
$6.573,309.57%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -100.00% | -37.05% | 44.63% | 63.98% | 92.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -100.00% | -37.05% | 44.63% | 63.98% | 92.72% |
| Operating Income | 100.00% | 37.05% | -44.63% | -63.98% | -92.72% |
| Income Before Tax | 100.00% | 33.78% | -66.86% | -269.76% | -1,203.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 100.00% | 33.78% | -66.86% | -269.76% | -1,203.81% |
| Earnings from Discontinued Operations | -2,264.46% | -2,547.13% | -3,033.76% | -3,205.91% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -220.18% | -301.57% | -427.27% | -675.51% | -1,376.69% |
| EBIT | 100.00% | 37.05% | -44.63% | -63.98% | -92.72% |
| EBITDA | 96.54% | 85.63% | 72.14% | 10.04% | -69.08% |
| EPS Basic | -220.06% | -321.56% | -499.65% | -973.74% | -732.30% |
| Normalized Basic EPS | 99.87% | 36.99% | -44.40% | -85.49% | -171.60% |
| EPS Diluted | -220.06% | -321.56% | -499.65% | -973.74% | -732.30% |
| Normalized Diluted EPS | 99.87% | 36.99% | -44.40% | -85.49% | -171.60% |
| Average Basic Shares Outstanding | 0.09% | 0.30% | 33.85% | 34.16% | 34.47% |
| Average Diluted Shares Outstanding | 0.09% | 0.30% | 0.52% | 0.68% | 0.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
